Tilt Investment Management Holdings PBC Sells 4,012 Shares of Johnson & Johnson (NYSE:JNJ)

Tilt Investment Management Holdings PBC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 29.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 9,807 shares of the company’s stock after selling 4,012 shares during the quarter. Johnson & Johnson accounts for about 1.7% of Tilt Investment Management Holdings PBC’s investment portfolio, making the stock its 9th largest position. Tilt Investment Management Holdings PBC’s holdings in Johnson & Johnson were worth $1,537,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Bond & Devick Financial Network Inc. boosted its stake in Johnson & Johnson by 6.4% in the 3rd quarter. Bond & Devick Financial Network Inc. now owns 6,531 shares of the company’s stock worth $1,017,000 after purchasing an additional 393 shares during the period. Worth Financial Advisory Group LLC boosted its stake in Johnson & Johnson by 4.9% in the 3rd quarter. Worth Financial Advisory Group LLC now owns 11,537 shares of the company’s stock worth $1,797,000 after purchasing an additional 542 shares during the period. Ritholtz Wealth Management boosted its stake in Johnson & Johnson by 90.9% in the 3rd quarter. Ritholtz Wealth Management now owns 41,394 shares of the company’s stock worth $6,447,000 after purchasing an additional 19,714 shares during the period. Arkadios Wealth Advisors boosted its stake in Johnson & Johnson by 54.3% in the 3rd quarter. Arkadios Wealth Advisors now owns 71,925 shares of the company’s stock worth $11,202,000 after purchasing an additional 25,298 shares during the period. Finally, Venture Visionary Partners LLC boosted its stake in Johnson & Johnson by 0.4% in the 3rd quarter. Venture Visionary Partners LLC now owns 99,877 shares of the company’s stock worth $15,558,000 after purchasing an additional 373 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms recently commented on JNJ. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Monday, April 15th. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Royal Bank of Canada decreased their target price on shares of Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating for the company in a research note on Wednesday, April 17th. Finally, Morgan Stanley decreased their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $175.86.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $149.56 on Wednesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. The firm has a market capitalization of $360.41 billion, a price-to-earnings ratio of 9.32, a P/E/G ratio of 2.44 and a beta of 0.53. The company’s fifty day moving average is $155.83 and its two-hundred day moving average is $155.51. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. The business’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period last year, the business posted $2.68 EPS. Equities research analysts forecast that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.32%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date is Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.